Abstract：
Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy and safety (improving upon those previously presented by the anti-IL-23 class). Material and methods. Retrospective analysis of a multicenter, observational study of real clinical practice, including patients with moderate-to-severe plaque psoriasis in treatment with risankizumab. This cross-sectional analysis includes information on patients from May 2020 to June 2022. A total of six tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows. Results. Regarding the percentage of patients who reached PASI 90 or PASI 100 at week 52, 92.5% achieved the therapeutic goal of PASI 90, and 78.5% reached PASI 100. When analyzing the results by absolute PASI, we found that 78.5% (n = 33) obtained PASI 0, 85.7% (n = 36) obtained PASI ≤ 1, and all patients achieved PASI ≤ 3 (disease control). Discussion. Risankizumab has shown promising results in the control of psoriasis in the long-term, with a high percentage of patients (>80%) maintaining PASI 90 and PASI 100 up to 52 weeks of treatment. No abnormal safety findings have been reported, and risankizumab appears to be a solid treatment in the different scenarios analyzed.
摘要：
背景：Risankizumab是免疫球蛋白G1（IgG1）型的人源化单克隆抗体，具有很高的亲和力，白细胞介素-23（IL-23）的p19亚基，导致与银屑病相关的炎症和临床症状的抑制。它的引入已设法提高了功效和安全性水平（改善了以前由抗IL-23类别提出的那些）。
方法：多中心回顾性分析，真实临床实践的观察性研究，包括接受risankizumab治疗的中度至重度斑块状银屑病患者.该横断面分析包括2020年5月至2022年6月的患者信息。安达卢西亚（西班牙）共有六家三级医院参加了这项研究。使用用于Windows的GraphPadPrism版本8.3.0进行“如观察到的”分析。
结果：关于第52周达到PASI90或PASI100的患者百分比，92.5％达到PASI90的治疗目标，78.5％达到PASI100。当通过绝对PASI分析结果时，我们发现78.5%(n=33)获得PASI0,85.7%(n=36)获得PASI≤1,所有患者获得PASI≤3(疾病控制)。
结论：Risankizumab在长期控制银屑病方面显示出了有希望的结果，高比例的患者（80％）维持PASI90和PASI100长达52周的治疗。没有异常的安全性发现报告，在分析的不同情况下，利沙单抗似乎是一种可靠的治疗方法。
方法：多中心回顾性分析，真实临床实践的观察性研究，包括接受risankizumab治疗的中度至重度斑块状银屑病患者.该横断面分析包括2020年5月至2022年6月的患者信息。安达卢西亚（西班牙）共有六家三级医院参加了这项研究。使用用于Windows的GraphPadPrism版本8.3.0进行“如观察到的”分析。
结果：关于第52周达到PASI90或PASI100的患者百分比，92.5％达到PASI90的治疗目标，78.5％达到PASI100。当通过绝对PASI分析结果时，我们发现78.5%(n=33)获得PASI0,85.7%(n=36)获得PASI≤1,所有患者获得PASI≤3(疾病控制)。
结论：Risankizumab在长期控制银屑病方面显示出了有希望的结果，高比例的患者（80％）维持PASI90和PASI100长达52周的治疗。没有异常的安全性发现报告，在分析的不同情况下，利沙单抗似乎是一种可靠的治疗方法。
